Herombopag Treated T-DM1 Induced Platelet Reduction

Summary

This is a single-arm study planned to enroll 56 breast cancer patients who experienced grade 2 or higher thrombocytopenia following prior chemotherapy and achieved normalization (platelet count ≥100 × 109/L and ≥200 × 109/L) through intervention.

Timeline

Start

2025-10-13

Primary completion

2026-09-26

Completion

2027-09-26

Drugs

Indications